GSK stock gets FDA approval for Nelkarmi lung cancer treatment
Published on 11/18/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew oncology approval broadens GSK's portfolio
- The FDA granted accelerated approval for Nelkarmi in previously treated ALK-positive non-small cell lung cancer.
- Trial results showed responses in patients treated with alectinib and in those exposed to multiple prior ALK therapies.
- The medicine came from GSK's acquisition of Nuvalent and is also being studied in earlier-line lung cancer.
On November 17, 2026, GSK announced that the US Food and Drug Administration had granted accelerated approval to Nelkarmi for previously treated ALK-positive non-small cell lung cancer. The RNS announcement said the approval covers adults with locally advanced or metastatic disease who have received either one prior ALK inhibitor consisting of alectinib, or at least two prior ALK inhibitors and platinum-based chemotherapy.
GSK stock traded at 22.52 euros on Lang & Schwarz at 12:08 CET on Wednesday, November 18, 2026.
Trial results support accelerated clearance
The regulatory decision was based on the phase I/II ALKOVE-1 trial, whose primary efficacy analysis included 222 patients with previously treated ALK-positive non-small cell lung cancer. Among 67 patients whose only prior ALK inhibitor was alectinib, the confirmed overall response rate was 49 percent, or 33 patients.
In the group of 155 patients who had received at least two prior ALK inhibitors and chemotherapy, the confirmed overall response rate was 32 percent, representing 50 patients. Among responders in the two groups, 76 percent and 69 percent, respectively, maintained their response for at least six months. The corresponding 12-month figures were 52 percent and 51 percent.
The trial also produced responses in patients with measurable central nervous system metastases. Intracranial response rates were 55 percent among patients previously treated only with alectinib and 26 percent among those who had received at least two prior ALK inhibitors and chemotherapy.
Nuvalent deal adds another cancer medicine
Nelkarmi is part of the portfolio acquired through GSK's purchase of Nuvalent. The approval is GSK's second lung cancer approval in 2026, adding another commercial asset to the company's effort to expand its oncology business.
GSK Chief Scientific Officer Tony Wood said the medicine was designed to address resistance mutations, disease affecting the brain and tolerability challenges. The company said Nelkarmi is being evaluated in ALKAZAR, an ongoing phase III study involving patients with ALK-positive non-small cell lung cancer who have not previously received an ALK inhibitor, as well as in other solid tumours.
The most common adverse reactions included hepatotoxicity, musculoskeletal pain, constipation, altered taste, peripheral neuropathy, edema and fatigue. Permanent discontinuation because of adverse reactions occurred in 5 percent of patients, with hepatotoxicity the most frequent reason.
Oncology remains a strategic focus
The approval gives investors a new regulatory milestone for GSK's oncology strategy while the company continues to develop medicines across lung, blood, gastrointestinal, genitourinary and gynecological cancers. The launch opportunity will depend on uptake in a previously treated patient population, further clinical development and the medicine's safety and durability profile.
GSK's next step is the commercial rollout in the United States and continued clinical work in earlier-line disease. The company has not presented Nelkarmi as a replacement for its broader pipeline; instead, the medicine forms part of a portfolio intended to deliver targeted treatments where resistance and limited options remain major challenges.
In the UK market, investors will also follow the FTSE 100, the principal index linked to GSK's home listing, through current market coverage.
GSK company profile
- Company: GSK plc
- ISIN: GB00BN7SWP63
- WKN: A3DMB5
- Frankfurt ticker: GS71
- Quote: 22.52 euros on Lang & Schwarz at 12:08 CET on November 18, 2026
- Index: FTSE 100
